贝伐珠单抗联合FOLFIRI方案治疗氟尿嘧啶耐药的晚期结直肠癌患者的疗效

doi:10.3969/j.issn.1671-7171.2025.02.026

摘要
图/表
参考文献(15)
相关文章 (15)

全文: PDF (1280 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨贝伐珠单抗联合FOLFIRI方案治疗氟尿嘧啶(FU)耐药的晚期结直肠癌患者的临床疗效。【方法】89例对FU耐药的晚期结直肠癌患者,随机分为对照组(44例,采用FOLFIRI方案治疗)和观察组(45例,采用贝伐珠单抗联合FOLFIRI方案治疗)。比较两组患者的近期及远期疗效,治疗前后肿瘤标志物水平和毒副反应发生情况。【结果】观察组近期总有效率高于对照组(P<0.05)。治疗后,两组血清糖链抗原19-9(CA19-9)、糖链抗原242(CA242)、癌胚抗原(CEA)、表皮生长因子受体(EGFR)水平均低于治疗前(P<0.05),且观察组低于对照组(P<0.05)。截至随访日期,对照组患者中位生存时间(OS)为12.0个月,观察组OS为17.0个月;两组Kaplan-Meier曲线比较,差异有统计学意义(Log-rank χ²=5.624,P=0.018)。两组患者各项毒副反应发生率比较,差异均无统计学意义(P>0.05)。【结论】贝伐珠单抗联合FOLFIRI方案治疗可提升FU耐药晚期结直肠癌患者的近远期疗效,降低肿瘤标志物水平,且安全可靠。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	孙振敏
	李婷

关键词 ：结直肠肿瘤, 贝伐珠单抗, 氟尿嘧啶, 治疗结果

Abstract：【Objective】To investigate the clinical efficacy of bevacizumab combined with the FOLFIRI regimen in treating fluorouracil (FU)-resistant advanced colorectal cancer (CRC) patients.【Methods】A total of 89 FU-resistant advanced colorectal cancer patients were randomly divided into two groups: the control group (44 patients, treated with the FOLFIRI regimen) and the observation group (45 patients, treated with bevacizumab combined with FOLFIRI regimen). The short-term and long-term efficacy, changes in tumor marker levels before and after treatment, and adverse reactions were compared between the two groups.【Results】The short-term overall response rate was significantly higher in the observation group than in the control group (P<0.05). After treatment, serum levels of carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 242 (CA242), carcinoembryonic antigen (CEA), and epidermal growth factor receptor (EGFR) were significantly lower than before treatment (P<0.05) in both groups, and the observation group had lower levels compared to the control group (P<0.05). At the end of the follow-up period, the median overall survival (OS) of the control group was 12.0 months, while the OS of the observation group was 17.0 months; the Kaplan-Meier curve comparison between the two groups showed a significant statistical difference (Log-rank χ²=5.624, P=0.018). There were no significant differences in the incidence of adverse reactions between the two groups (P>0.05).【Conclusion】Bevacizumab combined with FOLFIRI regimen treatment improves both short- and long-term efficacy in FU-resistant advanced colorectal cancer patients, reduces tumor marker levels, and it is safe and reliable.

Key words： Colorectal Neoplasms Bevacizumab Fluorouracil Treatment Outcome

收稿日期: 2023-10-06

中图分类号:

R735.35

引用本文:

孙振敏, 李婷. 贝伐珠单抗联合FOLFIRI方案治疗氟尿嘧啶耐药的晚期结直肠癌患者的疗效[J]. 医学临床研究, 2025, 42(2): 265-267.
SUN Zhenmin, LI Ting. Efficacy of Bevacizumab Combined with FOLFIRI Regimen in the Treatment of Fluorouracil-Resistant Advanced Colorectal Cancer. JOURNAL OF CLINICAL RESEARCH, 2025, 42(2): 265-267.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2025.02.026 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2025/V42/I2/265

[1] FRANCIPANE M G, BULANIN D, LAGASSE E. Establishment and characterization of 5-fluorouracil-resistant human colorectal cancer stem-like cells: tumor dynamics under selection pressure[J].Int J Mol Sci,2019, 20(8):1817.
[2] 李小峰, 孙新宇, 郝光军, 等. 腹腔内贝伐珠单抗辅助卵巢癌术后化疗对患者血清AFP、VEGF、TGF-β1、MIF的影响[J].现代生物医学进展, 2022, 22(2):379-382.
[3] 李金燕, 吕伯乐, 吕姗, 等. 贝伐珠单抗联合化疗对晚期肺癌患者血清肿瘤标志物及免疫功能的影响[J].癌症进展, 2021, 19(18):1896-1899.
[4] 姚宏伟, 刘荫华. NCCN结直肠癌临床实践指南2011年更新解读[J].中华胃肠外科杂志, 2011, 14(4):234-238.
[5] LITIÈRE S, ISAAC G, DE VRIES E G E, et al. RECIST 1.1 for response evaluation apply not only to chemotherapy-treated patients but also to targeted cancer agents: a pooled database analysis[J].J Clin Oncol,2019, 37(13):1102.
[6] HUGHES R. NCI-CTC vs TNS: which tool is better for grading the severity of chemotherapy-induced peripheral neuropathy?[J].Nat Clin Pract Neurol,2008, 4(2):68-69.
[7] DEKKER E, TANIS P J, VLEUGELS J L A,et al. Colorectal cancer[J].Lancet,2019, 394(10207):1467-1480.
[8] KONG F, MUIR J. 5-Fluorouracil: friend or foe?[J].Aust J Gen Pract,2021, 50(8):557-559.
[9] SCHMITT M, GRETEN F R. The inflammatory pathogenesis of colorectal cancer[J].Nat Rev Immunol,2021, 21(10):653-667.
[10] LI J, MA X, CHAKRAVARTI D, et al. Genetic and biological hallmarks of colorectal cancer[J].Genes Dev,2021, 35(11-12):787-820.
[11] 王奇龙, 陈南征, 吕铁升. 血清CEA、CA19-9、CA242对结直肠癌转移及预后的评估价值[J].解放军医药杂志, 2020, 32(6):29-33.
[12] ENRÍQUEZ-ACEVES I, GALICIA-CARMONA T, CORONEL-MARTÍNEZ JA, et al. Standard treatment with bevacizumab as targeted therapy in cervical cancer[J].Rev Invest Clin,2020, 72(4):213-218.
[13] ZHU M, COSTELLO B A, YIN J, et al. Phase Ⅱ trial of bevacizumab monotherapy in pancreatic neuroendocrine tumors[J].Pancreas,2021, 50(10):1435-1439.
[14] PRAGER G W, TAIEB J, FAKIH M, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer[J].N Engl J Med,2023, 388(18):1657-1667.
[15] SEHNALOVÁ I,ŘÍHOVÍ B, DEMLOVÁ R. Bevacizumab treatment in metastatic colorectal carcinoma:an economic perspective[J].Ceska Slov Farm,2019, 68(2):43-47.